Orthopedic Surgeon Guide to Adipose Banking Integration
Orthopedic surgeons are increasingly asked about adipose-derived stem cells, and recent state legislation in Florida and Wyoming has sharpened interest in how a banking service might fit a practice. This guide gives the operational picture: what those laws actually do, what the musculoskeletal evidence honestly shows, how a harvest integrates into existing procedures, and the […]
The Adipose-Derived Stem Cell Market in 2026: Science, Pipeline, and What It Means for Patients Who Bank Today
The adipose-derived stem cell market is one of the most active segments in regenerative medicine in 2026, driven by over four hundred active clinical trials, the December 2024 FDA approval of the first MSC-based biologic, and a growing body of published research documenting the multipotent and immunomodulatory properties of ADSCs across orthopedic, autoimmune, neurological, and […]
How to Introduce Stem Cell Banking to Patients Without Overstepping Compliance Lines
The most common reason physicians hesitate before introducing stem cell banking to patients is not skepticism about the science. It is uncertainty about what they are allowed to say. The distinction between permissible and impermissible language in this space is precise, and getting it wrong carries real professional and regulatory risk. This guide provides a […]
Expanded Access Programs: How Patients Can Legally Access Investigational Therapies
Expanded Access, sometimes called compassionate use, is the FDA’s formal pathway for certain patients with serious or immediately life-threatening diseases to access investigational products outside of clinical trials when specific criteria are met. It is a regulated, structured process governed by federal law, and it is distinct from both clinical trials and “Right-to-Try” legislation. This […]
